Allianz Asset Management
AKRO

Allianz Asset Management’s Akero Therapeutics AKRO Stock Holding History

Allianz Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,000
Closed -$807K – 1987
2025
Q3 		$807K Hold
17,000
– – ﹤0.01% 1756
2025
Q2 		$907K Buy
17,000
+4,200
+33% +$191K ﹤0.01% 1694
2025
Q1 		$518K Buy
+12,800
New +$543K ﹤0.01% 1865

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Allianz Asset Management's AKRO Position: Q4 2025 in Review

Allianz Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 17,000 shares — an estimated $807K sold.

Allianz Asset Management first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $907K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Allianz Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Allianz Asset Management sold 17,000 Akero Therapeutics shares in Q4 2025, an estimated $807K.
  • Allianz Asset Management first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
  • Allianz Asset Management's Akero Therapeutics position peaked at $907K in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Allianz Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.